Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

L.A. McKeown

April 16, 2024

News Conference News SCAI 2022

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

L.A. McKeown

May 23, 2022

News Daily News

Robert M. Califf Becomes 25th Commissioner of the US FDA

L.A. McKeown

February 15, 2022

News Daily News

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

L.A. McKeown

June 20, 2019

News Daily News

US Data Convey the Scope of Bleeding in Lower-Extremity Peripheral Interventions

Caitlin E. Cox

June 18, 2019

News Industry News

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease

April 26, 2018

News Conference News ACC 2017

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

Shelley Wood

March 23, 2017

News Conference News AHA 2016

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

Yael L. Maxwell

November 13, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

News Conference News VIVA 2016

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

L.A. McKeown

September 21, 2016

Advertisement

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

Robert M. Califf Becomes 25th Commissioner of the US FDA

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

US Data Convey the Scope of Bleeding in Lower-Extremity Peripheral Interventions

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Long PAD Lesions Respond Well to DCB, but Optimal Patient Selection Still Unclear

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content